Sign up
Quantellect · Analysts · Analyst Profile

Prakhar Agrawal

Cantor Fitzgerald · Equity Research Analyst

Analyst rating accuracy & track record

Prakhar Agrawal does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
MDGLMadrigal Pharmaceuticals Inc
Buy—Nov 2025−45.9%—
MDGLMadrigal Pharmaceuticals Inc
Buy—Nov 2025−47.2%—
ACRSAclaris Therapeutics Inc
Buy—Oct 2025+44.7%—
ORICOric Pharmaceuticals Inc
Buy—Sep 2025−12.9%—
AVTXAvalo Therapeutics Inc
Buy—Aug 2025+95.7%—
AVTXAvalo Therapeutics Inc
Buy—Aug 2025+95.7%—
ARDXArdelyx Inc
Buy—Jul 2025−3.3%—
GPCRStructure Therapeutics Inc. American Depositary Shares
Buy$65.00Jun 2025+88.6%Hit
ROIVRoivant Sciences Ltd
Buy—Jun 2025+160.3%—
ORICOric Pharmaceuticals Inc
Buy—May 2025+88.5%—
ACRSAclaris Therapeutics Inc
Buy—Mar 2025+134.2%—
ATYRaTyr Pharma, Inc.
Buy—Jan 2025−96.5%—
GPCRStructure Therapeutics Inc. American Depositary Shares
Buy$65.00Sep 2024−35.9%Miss
TCRTAlaunos Therapeutics Inc
Buy$3.00Jul 2022−67.6%Hit
Prev1Next
Go to

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.